logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics continues to progress clinical assets into FY2020

If GDC-0084 is successful in phase-III, the drug will launch into a disease area that has been poorly served by the last two decades of progress in cancer treatment.

Kazia Therapeutics Ltd - Kazia Therapeutics Ltd continues to progress world-class clinical assets into FY2020
Kazia is an oncology focused biotechnology company developing anti-cancer drugs

Kazia Therapeutics Ltd (ASX:KZA) continues to progress the development of its potentially world-class clinical assets beyond the 2019 financial year.

At June 30 Kazia had more than A$5.6 million in net current assets available for funding programs into the 2020 financial year.

In the company’s recent annual report Kazia chairman Iain Ross said the company had achieved all developmental, operational and clinical milestones set for itself.

“The drug has attracted considerable attention”

He said: “GDC-0084, our treatment for glioblastoma and DIPG is now in five clinical trials covering three entirely distinct patient populations at nine world-renowned international centres of excellence, many of which have requested to be involved in.

“In some cases, the centres have been prepared to independently fund the development of this new exciting drug.

“Given the fundamental value we see in GDC-0084, a potential development would need to meet a high hurdle but the growing excitement of clinicians and researchers for the drug has attracted considerable attention.”

With Cantrixil, the treatment for ovarian cancer Ross added the drug had progressed with clear signals of activity in patients.

“We have increasing confidence that both our programs are tacking to their respective milestones.”

Kazia’s chief executive officer James Garner said reaching six clinical trials over the last 12 months showed Kazia had come a long way in a short time.

“Four of our studies are primarily funded by sources external to Kazia, either the hospitals by whom they are being conducted or by the US-National Cancer Institute.

“This support creates enormous leverage for Kazia.”

Kazia is set to become a late-stage clinical company in 2020.

Quick facts: Kazia Therapeutics Ltd

Price: 0.62 AUD

ASX:KZA
Market: ASX
Market Cap: $38.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 11/24/2019

2 min read